ORCID Profile
0000-0001-5620-2646
Current Organisation
University of Tasmania
Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the Feedback Form.
Publisher: Springer Science and Business Media LLC
Date: 11-02-2022
Publisher: Springer Science and Business Media LLC
Date: 06-01-2021
DOI: 10.1186/S13071-020-04500-9
Abstract: Sarcoptic mange causes significant animal welfare and occasional conservation concerns for bare-nosed wombats ( Vombatus ursinus ) throughout their range. To date, in situ chemotherapeutic interventions have involved macrocytic lactones, but their short duration of action and need for frequent re-administration has limited treatment success. Fluralaner (Bravecto® MSD Animal Health), a novel isoxazoline class ectoparasiticide, has several advantageous properties that may overcome such limitations. Fluralaner was administered topically at 25 mg/kg ( n = 5) and 85 mg/kg ( n = 2) to healthy captive bare-nosed wombats. Safety was assessed over 12 weeks by clinical observation and monitoring of haematological and biochemical parameters. Fluralaner plasma pharmacokinetics were quantified using ultra-performance liquid chromatography and tandem mass spectrometry. Efficacy was evaluated through clinical assessment of response to treatment, including mange and body condition scoring, for 15 weeks after topical administration of 25 mg/kg fluralaner to sarcoptic mange-affected wild bare-nosed wombats ( n = 3). Duration of action was determined through analysis of pharmacokinetic parameters and visual inspection of study subjects for ticks during the monitoring period. Methods for diluting fluralaner to enable ‘pour-on’ application were compared, and an economic and treatment effort analysis of fluralaner relative to moxidectin was undertaken. No deleterious health impacts were detected following fluralaner administration. Fluralaner was absorbed and remained quantifiable in plasma throughout the monitoring period. For the 25 mg/kg and 85 mg/kg treatment groups, the respective means for maximum recorded plasma concentrations (C max ) were 6.2 and 16.4 ng/ml for maximum recorded times to C max , 3.0 and 37.5 days and for plasma elimination half-lives, 40.1 and 166.5 days. Clinical resolution of sarcoptic mange was observed in all study animals within 3–4 weeks of treatment, and all wombats remained tick-free for 15 weeks. A suitable product for diluting fluralaner into a ‘pour-on’ was found. Treatment costs were competitive, and predicted treatment effort was substantially lower relative to moxidectin. Fluralaner appears to be a safe and efficacious treatment for sarcoptic mange in the bare-nosed wombat, with a single dose lasting over 1–3 months. It has economic and treatment-effort-related advantages over moxidectin, the most commonly used alternative. We recommend a dose of 25 mg/kg fluralaner and, based on the conservative assumption that at least 50% of a dose makes dermal contact, Bravecto Spot-On for Large Dogs as the most appropriate formulation for adult bare-nosed wombats.
Publisher: Springer Science and Business Media LLC
Date: 05-03-2021
DOI: 10.1186/S13071-021-04658-W
Abstract: An amendment to this paper has been published and can be accessed via the original article.
Publisher: Wiley
Date: 24-11-2023
Abstract: Interventions against infectious diseases in wildlife are increasingly necessary but remain problematic. Dissimilar to public and domestic animal health, pharmacological interventions (PIs) are rarely used against disease in wildlife populations. However, drugs can combat a range of pathogen types while aligning with positive ethical, epidemiological, evolutionary and socio‐economic outcomes. We discuss how recent conceptual and technological advances could overcome barriers, improve safety and begin a new era of contemporary wildlife management that embraces PIs. We then provide a framework that supports an objective comparison of intervention suitability, including PIs. We find numerous directions for PI optimisation through innovation and transdisciplinary collaboration and demonstrate the utility of the framework for judging the appropriateness of a PI. Synthesis and applications : Interrogating how and when pharmacological interventions can be used to the greatest effect reduces risks and improves outcomes for wildlife, while empowering decision makers to draw from the full suite of intervention methods to find the most appropriate disease management solutions.
Publisher: Wildlife Disease Association
Date: 09-10-2019
DOI: 10.7589/2018-08-191
Abstract: Two adult Great Spotted Woodpeckers (
Location: United Kingdom of Great Britain and Northern Ireland
No related grants have been discovered for Vicky Wilkinson.